KGbio
Steven Amadeus has a diverse background and experience in various industries. Currently serving as the IT Manager / Head at Kalbio Global Medika, Steven has also held positions such as IT Quality Supervisor and Production Scientist in the past. With a Bachelor of Science in Biotechnology, Steven has also worked in research, statistics, chemistry, and laboratory assistance roles. Steven's educational background includes courses in Business Administration from The Wharton School. Currently, Steven is managing IT projects and operationals at multiple companies.
This person is not in any teams
KGbio
KGbio is a clinical-stage biotechnology company focused on bringing biologics medical innovation to markets outside the US/Canada, Western Europe and China. The business model revolves around in-licensing novel biologics and select biosimilars in oncology and high-specialty therapeutic areas (typically pre-IND or early clinical stage), with the objective to out-license them in target geographies after finishing clinical development as well as regulatory and reimbursement approvals. Platforms of interest currently include Fc-fusion proteins, antibodies, bispecifics, ADCs, cell therapies and therapeutic vaccines. The company is backed by Asian pharma companies Kalbe (market cap US$5.5 billion) and Genexine (market cap US$1.3 billion) and US private equity giant General Atlantic (AUM US$ 78 billion).